Investigational Drug Details
| Drug ID: | D210 |
| Drug Name: | Lovaza |
| Synonyms: | Omega-3 fatty acid ethyl esters; Omega-3-acid ethyl esters |
| Type: | Chemical drug |
| DrugBank ID: | DB09539 |
| DrugBank Description: | Omega-3-acid ethyl esters are prescription drugs that contain eicosapentaenoic acid-ethyl ester (EPA) and docosahexaenoic acid-ethyl ester (DHA) that are used in combination with changes in diet to lower triglyceride levels in adults with severe (≥ 500 mg/dL) hypertriglyceridemia. Omega-3-acid ethyl esters are currently marketed in the US, EU, and many other regions under the brand name Lovaza. |
| PubChem ID: | 9831414 |
| CasNo: | 861006-80-6 |
| Repositioning for NAFLD: | Yes |
| SMILES: | C(=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)\CCC(=O)OCC.C(=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)\CCCC(=O)OCC |
| Structure: |
|
| InChiKey: | DTMGIJFHGGCSLO-FIAQIACWSA-N |
| Molecular Weight: | 687.062 |
| DrugBank Targets: | Sterol regulatory element-binding protein 1 inhibitor |
| DrugBank MoA: | Omega-3-acid ethyl esters reduce triglyceride production by the liver but this mechanism is not well understood. Omega-3-acid ethyl esters inhibit acyl-CoA:1,2-diacylglycerol acyltransferase, reducing triglyceride synthesis and increasing paroxysmal beta-oxidation, which increases fatty aside metabolism. Omega-3-acid ethyl esters also inhibit the release of fatty acids by competing for enzymes involved in the synthesis of triglycerides, increase triglyceride clearance by increasing the activity of lipoprotein lipase, and decrease production of VLDL-C. |
| DrugBank Pharmacology: | Omega-3-acid ethyl esters reduce triglyceride production, increase fatty acid metabolism, inhibit the release of fatty acids, increase triglyceride clearance, and decrease production of very low density lipoprotein cholesterol(VLDL-C). |
| DrugBank Indication: | Omega-3-Acid Ethyl Esters capsules, USP are indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia (HTG). |
| Targets: | SREBF1 inhibitor |
| Therapeutic Category: | Hypolipidemic drug |
| Clinical Trial Progress: | Clinical trial on-going (NCT00941642) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0012 | NCT00941642 | Phase 4 | Unknown status | No Results Available | September 2009 | June 10, 2010 | Details |
| L0252 | NCT00845845 | Phase 2 | Terminated | Has Results | March 2006 | July 24, 2013 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A18472 | 27106721 | Diabetologia | Higher body fat percentage is associated with enhanced temperature perception in NAFLD: results from the randomised Wessex Evaluation of fatty Liver and Cardiovascular markers in NAFLD with OMacor thErapy trial (WELCOME) trial. | Details |
| A19121 | 26748347 | Atherosclerosis | Improvement in non-alcoholic fatty liver disease severity is associated with a reduction in carotid intima-media thickness progression. | Details |
| A21791 | 25043514 | Hepatology | Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome* study. | Details |